Enzon Inc. (NASDAQ:ENZN) of Piscataway, N.J., announcedWednesday that it has granted Hybritech Inc., an Eli Lillysubsidiary, a non-exclusive license to its single-chain antigen-binding (SCA) protein technology. R. Douglas Hulse, Enzon's vicepresident of business technology, said, "This agreementrepresents a major step in our licensing program for the SCAprotein technology." Enzon announced a similar agreement withBaxter International Inc. on Monday.

(c) 1997 American Health Consultants. All rights reserved.